Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Promethera Biosciences

http://www.promethera.com/

Latest From Promethera Biosciences

Aeglea’s Rare Disease Asset Succeeds At Phase III, In Line To Become First Product

The firm’s lead candidate has shown promise in a pivotal rare disease study, setting it on track for an upcoming BLA catalyst which could lead to Aeglea’s first approved product.

Clinical Trials Rare Diseases

Asia Deal Watch: Promethera Calls On Hao Tian For Asian JV To Advance Its Liver Candidates

Plus recent deals involving BeiGene, Assembly Biosciences, Piramal, Medivant, Revitope, Junshi, JW Therapeutics, Eureka, Acepodia, Chiesi, Bayer, NewG Lab, AnHeart

Deals M & A

Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili

Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.

Asia Pacific Deals

Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program

AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Baliopharm AG
    • Promethera Biosciences Japan Branch Ltd
UsernamePublicRestriction

Register